Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation (GKOS) is a leader in ophthalmic medical technology, pioneering micro-invasive glaucoma surgery (MIGS) and transformative eye care solutions. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements, regulatory milestones, and strategic initiatives.
Access timely press releases covering product approvals, financial results, and research developments directly impacting glaucoma treatment paradigms. Our curated collection includes updates on therapeutic innovations, partnership announcements, and progress in addressing various stages of ocular disease.
Bookmark this page for streamlined access to Glaukos' latest achievements in medical device engineering and surgical techniques. Regularly updated content ensures you stay informed about developments influencing both patient care and the evolving ophthalmic technology landscape.
Glaukos (NYSE: GKOS) reported record Q3 2025 net sales of $133.5M, up 38% YoY (37% constant currency), driven by glaucoma sales of $110.2M (+45% YoY) and U.S. glaucoma sales of $80.8M (+57% YoY). Gross margin was ~78% and non-GAAP gross margin ~84% for Q3 2025. GAAP net loss was $16.2M (loss of $0.28 per diluted share); non-GAAP net loss was $9.2M (loss of $0.16 per diluted share). Cash and equivalents plus short-term investments totaled ~$277.5M and the company reported no debt. Management raised 2025 net sales guidance to $490M–$495M and provided preliminary 2026 net sales guidance of $600M–$620M.
Glaukos (NYSE:GKOS) announced FDA approval of Epioxa HD / Epioxa, the first FDA‑approved incision‑free topical drug therapy for keratoconus, a rare sight‑threatening corneal disease. Approval was supported by two randomized, double‑masked Phase 3 trials that randomized over 400 patients and met primary efficacy endpoints with favorable tolerability. Epioxa uses sequential topical formulations activated by UV in an oxygen‑enriched environment to perform corneal cross‑linking without removing the epithelium. Glaukos expects commercial availability in Q1 2026 and plans investments in patient awareness, access programs, and co‑pay assistance.
Glaukos (NYSE:GKOS) will feature technologies and scientific posters at the American Academy of Ophthalmology (AAO) Annual Meeting in Orlando, October 18–20, 2025, and will exhibit onsite at booth #2921.
Highlighted content includes glaucoma posters on Travoprost intracameral implant (iDose TR) with up to 36-month topical medication reduction and Month 12 cataract-surgery outcomes, corneal health Phase 3 data for epithelium-on CXL, and presentations on oxygen-supplemented/topography-guided epithelium-on CXL and IRIS Registry analysis of CXL failure rates. Two timed presentations: Oct 17, 2025 at 1:55 p.m. ET and Oct 18, 2025 at 11:18 a.m. ET. Abstracts available at www.aao.org/annual-meeting.
Glaukos (NYSE:GKOS) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025. Management will discuss results on a conference call and simultaneous webcast at 1:30 p.m. PT / 4:30 p.m. ET on October 29, 2025.
A live webcast link will be available at http://investors.glaukos.com. To join the call dial 800-715-9871 (U.S.) or 646-307-1963 (International) and enter Conference ID 5255602. A replay will be archived on the investor website after the call.
Glaukos (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, has broken ground on a new 200,000 square-foot research, development, and manufacturing facility in Huntsville, Alabama. The project represents a planned investment of over $80 million and is expected to create more than 150 full-time jobs in the region.
The company selected Huntsville from over 100 potential sites worldwide, citing the area's strong talent base and vibrant business climate. Located in Cummings Research Park, the facility will be built on 25 acres with an option for an additional 15 acres for future expansion. The project is scheduled for completion by 2030 and aims to strengthen U.S. manufacturing capabilities while supporting Glaukos' long-term growth plans.
Glaukos Corporation (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology solutions for glaucoma, corneal disorders, and retinal diseases, has announced its upcoming participation in the Wells Fargo Healthcare Conference.
The presentation is scheduled for September 3, 2025, at 10:15 a.m. ET in Boston, MA. Investors can access both live and archived webcasts of the event through the Investors section of Glaukos's website at investors.glaukos.com.
Glaukos (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, reported strong Q2 2025 financial results with record net sales of $124.1 million, marking a 30% year-over-year increase. The company's Glaucoma segment achieved record sales of $103.5 million, up 36% year-over-year, with U.S. Glaucoma sales reaching $72.3 million, a 45% increase.
Key financial metrics include a gross margin of 78% (83% non-GAAP), though the company reported a net loss of $19.7 million ($0.34 per share). The company maintains a strong financial position with $278.6 million in cash and investments with no debt. Based on strong performance, Glaukos raised its 2025 net sales guidance to $480-486 million from the previous $475-485 million range.
[ "Record net sales of $124.1M, up 30% year-over-year", "Strong Glaucoma segment growth with 36% YoY increase to $103.5M", "U.S. Glaucoma sales up 45% YoY to $72.3M", "Improved gross margin to 78% (83% non-GAAP)", "Raised 2025 revenue guidance to $480-486M", "Strong balance sheet with $278.6M cash and no debt" ]Glaukos Corporation (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology, has scheduled the release of its second quarter 2025 financial results after market close on Wednesday, July 30, 2025.
The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Investors can access the live webcast through the company's investor relations website, or join via phone using the provided dial-in numbers and Conference ID 5255602.
Glaukos (NYSE: GKOS) has received European Union Medical Device Regulation (MDR) certification for its iStent infinite® and iStent inject® W micro-invasive glaucoma surgery (MIGS) technologies. These are the company's first approvals under the new EU regulatory framework.
The iStent® platform involves micro-scale surgical devices that reduce intraocular pressure by restoring natural aqueous humor outflow pathways in glaucoma patients. The company's MIGS technologies are supported by nearly 400 peer-reviewed publications and have achieved over one million implants worldwide.
Glaukos (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, will celebrate its 10th IPO anniversary by ringing the NYSE Closing Bell on June 25, 2025. CEO Thomas Burns highlighted the company's transformation from a single-product, U.S.-focused entity to a global ophthalmology leader with over 1,000 employees.
The ceremonial event marks a decade of growth in developing therapies for glaucoma, corneal disorders, and retinal diseases. The closing bell ceremony will be live-streamed on the NYSE website and may be broadcast on various media outlets including CNBC.
FAQ
What is the current stock price of Glaukos (GKOS)?
What is the market cap of Glaukos (GKOS)?
